Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Assets (2022 - 2025)

Corvus Pharmaceuticals has reported Other Non-Current Assets over the past 4 years, most recently at $852000.0 for Q3 2025.

  • Quarterly results put Other Non-Current Assets at $852000.0 for Q3 2025, up 238.1% from a year ago — trailing twelve months through Sep 2025 was $852000.0 (up 238.1% YoY), and the annual figure for FY2024 was $632000.0, up 610.11%.
  • Other Non-Current Assets for Q3 2025 was $852000.0 at Corvus Pharmaceuticals, up from $626000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for CRVS hit a ceiling of $852000.0 in Q3 2025 and a floor of $89000.0 in Q3 2023.
  • Median Other Non-Current Assets over the past 4 years was $236000.0 (2022), compared with a mean of $299600.0.
  • Biggest five-year swings in Other Non-Current Assets: crashed 64.11% in 2023 and later surged 610.11% in 2024.
  • Corvus Pharmaceuticals' Other Non-Current Assets stood at $129000.0 in 2022, then tumbled by 31.01% to $89000.0 in 2023, then surged by 610.11% to $632000.0 in 2024, then skyrocketed by 34.81% to $852000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $852000.0 (Q3 2025), $626000.0 (Q2 2025), and $629000.0 (Q1 2025) per Business Quant data.